SlideShare a Scribd company logo
1 of 21
FOCUSED. TRUSTED. GLOBAL.




                  Vendor Qualification
                  Vendor Management
               from a CRO QM standpoint
                            Dr. Ursula Schlichtiger
                             Zurich May 9, 2012
FOCUSED. TRUSTED. GLOBAL.
FOCUSED. TRUSTED. GLOBAL.




   Who is a Vendor?
   Anybody contracted or
   subcontracted to be involved in a
   clinical trial

   • Company
   • Person
   • Institution
   • Organisation
FOCUSED. TRUSTED. GLOBAL.



   Vendors/ Subcontractors

         Sponsor
                                               bound per contract
          Vendors CRO
                                               bound per contract
                      Vendors Subcontractors



      ? 1. Who holds the contract?
        2. Which tasks are delegated?
FOCUSED. TRUSTED. GLOBAL.



   Regulatory Background Europe (1)
      Commission Directive 2005/28/EC
       “GCP Directive”
       http://ec.europa.eu/health/files/eudralex/vol-1/dir_2005_28/dir_2005_28_en.pdf




     Chapter 2, THE SPONSOR, Article 7
   A sponsor may delegate any or all of his trial-related functions to
      an individual, a company, an institution or an organization.
   However, in such cases, the sponsor shall remain responsible for
      ensuring that the conduct of the trials and the final data
      generated by those trials comply with Directive 2001/20/EC as
      well as this Directive.
FOCUSED. TRUSTED. GLOBAL.



   Regulatory Background Europe (2)
      European Commission: Eudralex Volume 10 Chapter IV

         Guidance Documents for Inspections:
         Annex IV to Guidance for the conduct of GCP Inspections -
         Sponsor and CRO“ (28 May 2008):

         http://ec.europa.eu/health/files/eudralex/vol10/chap4/annex_iv_to_guidance_for_the_conduct_of_gcp_inspections-


         o 2. SPONSOR OR CRO QUALITY SYSTEM INSPECTION
         o 3. SPECIFIC CLINICAL TRIAL INSPECTION
FOCUSED. TRUSTED. GLOBAL.



   Regulatory Background Europe (cont 2)
   2. SPONSOR OR CRO QUALITY SYSTEM INSPECTION:
   The aim of this kind of inspection is to evaluate the quality assurance and quality
      control systems established by the sponsor/CRO in order to assure that clinical
      trials are conducted and data are generated, recorded and reported in
      compliance with the protocol, GCP and applicable regulatory requirements.
   The following items should be reviewed in a sponsor/CRO system inspection:
   2.3.8 Sponsor audit and quality assurance system
   The aim is to determine if the sponsor/CRO has established an audit system, as
        part of its own quality assurance system, in order to evaluate its activities
        related to clinical trials.
   It should be determined if the procedures include:
    Audits of key clinical trial processes, including monitoring, data management,
        safety reporting, clinical study report production, archiving and computer
        system validation activities
    Audits of contractors/subcontractors
FOCUSED. TRUSTED. GLOBAL.



   Regulatory Background Europe (cont 2)
   The inspectors should also review:
    The processes for communicating and addressing audit findings, including the
      format and distribution of audit reports
    The procedures for dealing with serious and/or persistent GCP non-
      compliance
    Audit trails
    Procedures for generation and implementation of audit program(s)/plan(s)

   2.3.9 Delegation of duties
   The aim is to verify the procedures for contracting/subcontracting of trial-related
       duties.
   Inspectors should examine the procedures related with:
    Pre-selection and ongoing assessment of contractor/subcontractors
    Documentation of duty delegation and its time recording
    Handling contract amendments
    Contracts should be reviewed (either specific ones or a sample)
FOCUSED. TRUSTED. GLOBAL.



   Regulatory Background Europe (cont 2)
   3. SPECIFIC CLINICAL TRIAL INSPECTION
   3.1 Implementation and termination of the clinical trial
   The aim is to determine if all legal and administrative aspects of the clinical trial
      have been accomplished.
   Review:
    Distribution of sponsor’s duties or functions
    ……



   3.8 Audit
   Determine:

      If the clinical trial was audited and if audit reports exist
      Qualifications of the auditors
FOCUSED. TRUSTED. GLOBAL.



   Consequences

      Sponsor and CRO:
        • Need a vendor qualification program
           » Internal vendors „Affiliates“
           » External vendors „Subcontractors“
               Risk based approach
               SOPs needed
FOCUSED. TRUSTED. GLOBAL.



   Risk based Vendor Qualification
   1.   High risk:          Delegation of critical tasks, e.g.
                            - CROs
                            - CMOs
                            - Depots with QP release
                            Audit mandatory

   o    Medium risk:        Delegation of routine tasks, e.g.
                            - Courier
                            - Depots without QP release
                            - Translation companies
                            paper based/ audit on case by case basis

   o    Low risk:           e.g.
                            - provider of commercially available material
                            paper based

   o    Freelancers
FOCUSED. TRUSTED. GLOBAL.



   CROs/ Subcontractors
      Prequalification (paper based)
       • by means of questionnaire and
         supporting documents, e.g.
           » SOP Index
           » QM Manual
           » CVs


      Qualification: Audit mandatory
FOCUSED. TRUSTED. GLOBAL.


   Depots
   with and without QP release
FOCUSED. TRUSTED. GLOBAL.



   Courier Services
      Courier Service Companies
       • Qualification by means of questionnaire and supporting
         documents, e.g.
           » ISO certificates, index of quality manual, system description
           » Transport validation
FOCUSED. TRUSTED. GLOBAL.



   Freelancers
                 Risk based vs. Realistic approach



                            paper based: CV
                             Training records
                             Personal experience

       audit of local situation:        security
FOCUSED. TRUSTED. GLOBAL.



   Goals?
      All Key Service
       Providers should be
       qualified.
      Keep a Qualified
       Vendor List
      Only Service Providers
       from the Qualified
       Vendor List should be
       chosen
      Train the operational
       functions
FOCUSED. TRUSTED. GLOBAL.



   Process
      Internal Vendor
       Qualification

      Identification of vendors
       prior to contracts issued

      Re-Qualification Audits
       foreseen every 2 years as per
       SOP
       includes "experience criteria"

      Qualification after
       contracting only in
       exceptional cases
FOCUSED. TRUSTED. GLOBAL.



   How can Operations help?
      Let QA know which Key
       Service
       Providers you plan to
       work with

      When selecting a vendor
       check the Qualified
       Vendor List

      Use Vendor Audit
       Request Form for new
       vendors

      Provide feedback on
       experience with vendors
FOCUSED. TRUSTED. GLOBAL.



   Request a Vendor Audit!
FOCUSED. TRUSTED. GLOBAL.



   Inspection/ Audit Questions
   1.    Are SOPs available?
   2.    Do you use vendors?
   3.    What kind of vendors?
   4.    Which are internal and which are external vendors?
   5.    How do you qualify them?
   6.    How often do you re-qualify them?
   7.    Which vendors have been qualified?
   8.    Why do you also allow paper-based qualification?
   9.    Can we get insight in the audit reports?
   10.   Does QA have GCP/ GLP and GMP experience?
   11.   Do you audit against Task Allocation?
FOCUSED. TRUSTED. GLOBAL.



   Thank you! Any Questions?
                            o   Medpace Medical Consulting GmbH
                                Nussbaumstr. 10
                                80336 Munich
                                Germany
                                Tel: +49 (0) 89 673 79 16
                                Fax: +49 (0) 89 670 21 00
                                E-mail: info-MC@medpace.com

More Related Content

What's hot

PHARMACEUTICAL VAILIDATION
PHARMACEUTICAL VAILIDATIONPHARMACEUTICAL VAILIDATION
PHARMACEUTICAL VAILIDATIONSayali Powar
 
Validation (intro, scope, merits, ich, who guidelines)
Validation (intro, scope, merits, ich, who guidelines)Validation (intro, scope, merits, ich, who guidelines)
Validation (intro, scope, merits, ich, who guidelines)PRAJAKTASAWANT33
 
Complaints and recall handling
Complaints and recall handlingComplaints and recall handling
Complaints and recall handlinghusna05
 
Incorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation PlanIncorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation PlanInstitute of Validation Technology
 
Self inspection
Self inspectionSelf inspection
Self inspectionBangaluru
 
Guidelinesfor processvalidationofpharmaceuticaldosageforms
Guidelinesfor processvalidationofpharmaceuticaldosageformsGuidelinesfor processvalidationofpharmaceuticaldosageforms
Guidelinesfor processvalidationofpharmaceuticaldosageformsRaj Agarwal
 
Second Party Audit and External Third Party Audit
Second Party Audit and External Third Party AuditSecond Party Audit and External Third Party Audit
Second Party Audit and External Third Party AuditShantanuThakre3
 
Quality Assurance : Audit And Inspection
Quality Assurance : Audit And InspectionQuality Assurance : Audit And Inspection
Quality Assurance : Audit And Inspectionprashanth
 
WHO GMP Requirements
WHO GMP  RequirementsWHO GMP  Requirements
WHO GMP RequirementsDeekshitha HS
 
Quality Metrics in Pharmaceuticals
Quality Metrics in PharmaceuticalsQuality Metrics in Pharmaceuticals
Quality Metrics in PharmaceuticalsPiyush Tripathi
 
QUALITY AUDITS
QUALITY AUDITSQUALITY AUDITS
QUALITY AUDITSMcpl Moshi
 

What's hot (20)

Supplier Selection
Supplier SelectionSupplier Selection
Supplier Selection
 
Quality Assurance
Quality AssuranceQuality Assurance
Quality Assurance
 
PHARMACEUTICAL VAILIDATION
PHARMACEUTICAL VAILIDATIONPHARMACEUTICAL VAILIDATION
PHARMACEUTICAL VAILIDATION
 
Six sigma QMS
Six sigma QMS Six sigma QMS
Six sigma QMS
 
Validation (intro, scope, merits, ich, who guidelines)
Validation (intro, scope, merits, ich, who guidelines)Validation (intro, scope, merits, ich, who guidelines)
Validation (intro, scope, merits, ich, who guidelines)
 
Complaints and recall handling
Complaints and recall handlingComplaints and recall handling
Complaints and recall handling
 
Incorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation PlanIncorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation Plan
 
Quality metrices
Quality metricesQuality metrices
Quality metrices
 
Self inspection
Self inspectionSelf inspection
Self inspection
 
Excipient Auditing
Excipient AuditingExcipient Auditing
Excipient Auditing
 
Guidelinesfor processvalidationofpharmaceuticaldosageforms
Guidelinesfor processvalidationofpharmaceuticaldosageformsGuidelinesfor processvalidationofpharmaceuticaldosageforms
Guidelinesfor processvalidationofpharmaceuticaldosageforms
 
Second Party Audit and External Third Party Audit
Second Party Audit and External Third Party AuditSecond Party Audit and External Third Party Audit
Second Party Audit and External Third Party Audit
 
Quality audit plan
Quality audit planQuality audit plan
Quality audit plan
 
Quality Assurance : Audit And Inspection
Quality Assurance : Audit And InspectionQuality Assurance : Audit And Inspection
Quality Assurance : Audit And Inspection
 
Pharmaceutical Auditing and Inspections Professor Peivand Pirouzi 2010
Pharmaceutical Auditing and Inspections   Professor Peivand Pirouzi 2010Pharmaceutical Auditing and Inspections   Professor Peivand Pirouzi 2010
Pharmaceutical Auditing and Inspections Professor Peivand Pirouzi 2010
 
WHO GMP Requirements
WHO GMP  RequirementsWHO GMP  Requirements
WHO GMP Requirements
 
Quality Metrics in Pharmaceuticals
Quality Metrics in PharmaceuticalsQuality Metrics in Pharmaceuticals
Quality Metrics in Pharmaceuticals
 
Quality Audit
Quality AuditQuality Audit
Quality Audit
 
QUALITY AUDITS
QUALITY AUDITSQUALITY AUDITS
QUALITY AUDITS
 
Process validation
Process validationProcess validation
Process validation
 

Viewers also liked

Effective Supplier Management: Because Knowing Is Better than Wondering
Effective Supplier Management: Because Knowing Is Better than WonderingEffective Supplier Management: Because Knowing Is Better than Wondering
Effective Supplier Management: Because Knowing Is Better than WonderingSAP Ariba
 
Clinical Supply Management with Siebel Clinical
Clinical Supply Management with Siebel ClinicalClinical Supply Management with Siebel Clinical
Clinical Supply Management with Siebel ClinicalPerficient
 
Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016
Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016
Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016Carestream
 
New summary interlaboratory & summary instrument group reports mar15 pol
New summary interlaboratory & summary instrument group reports mar15 polNew summary interlaboratory & summary instrument group reports mar15 pol
New summary interlaboratory & summary instrument group reports mar15 polRandox
 
Herramientas wep 2.0 informatica
Herramientas wep 2.0 informaticaHerramientas wep 2.0 informatica
Herramientas wep 2.0 informaticaOswaldox
 
Direct Mail Design
Direct Mail DesignDirect Mail Design
Direct Mail Designunderwoodco
 
Reunión en grupo .tecnicas cualitativas
Reunión en grupo .tecnicas cualitativasReunión en grupo .tecnicas cualitativas
Reunión en grupo .tecnicas cualitativasLaura Lacuna
 
Guía de playas en Boiro 2013
Guía de playas en Boiro 2013Guía de playas en Boiro 2013
Guía de playas en Boiro 2013Arousa Norte
 
Il lavoro di Seth
Il lavoro di SethIl lavoro di Seth
Il lavoro di SethprofSV
 
Pesticide Research & the Politics of Poisoning for Profits
Pesticide Research & the Politics of Poisoning for Profits Pesticide Research & the Politics of Poisoning for Profits
Pesticide Research & the Politics of Poisoning for Profits v2zq
 
Bodas invitaciones
Bodas invitacionesBodas invitaciones
Bodas invitacionesAyyelen
 
How to promote your Gentlemen's Club using Facebook Ads
How to promote your Gentlemen's Club using Facebook AdsHow to promote your Gentlemen's Club using Facebook Ads
How to promote your Gentlemen's Club using Facebook AdsBrett Battle
 
Segmentierung,crm,positionierung
Segmentierung,crm,positionierungSegmentierung,crm,positionierung
Segmentierung,crm,positionierungstefanjenny
 
Works and influences of hendrik petrus berlage.pptx final
Works and influences of hendrik petrus berlage.pptx finalWorks and influences of hendrik petrus berlage.pptx final
Works and influences of hendrik petrus berlage.pptx finalaashish gupta
 

Viewers also liked (20)

Effective Supplier Management: Because Knowing Is Better than Wondering
Effective Supplier Management: Because Knowing Is Better than WonderingEffective Supplier Management: Because Knowing Is Better than Wondering
Effective Supplier Management: Because Knowing Is Better than Wondering
 
Clinical Supply Management with Siebel Clinical
Clinical Supply Management with Siebel ClinicalClinical Supply Management with Siebel Clinical
Clinical Supply Management with Siebel Clinical
 
Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016
Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016
Evaluating Enterprise Clinical Data-Management Systems at RSNA 2016
 
La cultura del hampa
La cultura del hampa La cultura del hampa
La cultura del hampa
 
New summary interlaboratory & summary instrument group reports mar15 pol
New summary interlaboratory & summary instrument group reports mar15 polNew summary interlaboratory & summary instrument group reports mar15 pol
New summary interlaboratory & summary instrument group reports mar15 pol
 
Conservus Brochure_1p
Conservus Brochure_1pConservus Brochure_1p
Conservus Brochure_1p
 
Herramientas wep 2.0 informatica
Herramientas wep 2.0 informaticaHerramientas wep 2.0 informatica
Herramientas wep 2.0 informatica
 
Presentacion
PresentacionPresentacion
Presentacion
 
Direct Mail Design
Direct Mail DesignDirect Mail Design
Direct Mail Design
 
Reunión en grupo .tecnicas cualitativas
Reunión en grupo .tecnicas cualitativasReunión en grupo .tecnicas cualitativas
Reunión en grupo .tecnicas cualitativas
 
Guía de playas en Boiro 2013
Guía de playas en Boiro 2013Guía de playas en Boiro 2013
Guía de playas en Boiro 2013
 
Il lavoro di Seth
Il lavoro di SethIl lavoro di Seth
Il lavoro di Seth
 
MANUAL OPENOFFICE DRAW
MANUAL OPENOFFICE DRAWMANUAL OPENOFFICE DRAW
MANUAL OPENOFFICE DRAW
 
Pesticide Research & the Politics of Poisoning for Profits
Pesticide Research & the Politics of Poisoning for Profits Pesticide Research & the Politics of Poisoning for Profits
Pesticide Research & the Politics of Poisoning for Profits
 
Pedro rocha
Pedro rochaPedro rocha
Pedro rocha
 
Bodas invitaciones
Bodas invitacionesBodas invitaciones
Bodas invitaciones
 
Wiesbaden Magazin Ausgabe Juni 2009
Wiesbaden Magazin Ausgabe Juni 2009Wiesbaden Magazin Ausgabe Juni 2009
Wiesbaden Magazin Ausgabe Juni 2009
 
How to promote your Gentlemen's Club using Facebook Ads
How to promote your Gentlemen's Club using Facebook AdsHow to promote your Gentlemen's Club using Facebook Ads
How to promote your Gentlemen's Club using Facebook Ads
 
Segmentierung,crm,positionierung
Segmentierung,crm,positionierungSegmentierung,crm,positionierung
Segmentierung,crm,positionierung
 
Works and influences of hendrik petrus berlage.pptx final
Works and influences of hendrik petrus berlage.pptx finalWorks and influences of hendrik petrus berlage.pptx final
Works and influences of hendrik petrus berlage.pptx final
 

Similar to Mmc vendor qualification and management -dr. ursula schlictiger-may2012

MDSAP Certification: Success and Failures
MDSAP Certification: Success and FailuresMDSAP Certification: Success and Failures
MDSAP Certification: Success and FailuresGreenlight Guru
 
Exporting to Uganda ? What is PvOC ?
Exporting to Uganda ? What is PvOC ?Exporting to Uganda ? What is PvOC ?
Exporting to Uganda ? What is PvOC ?Mugula Joseph
 
For those interested in Healthcare Fieldwork services - please take a look!
For those interested in Healthcare Fieldwork services - please take a look!For those interested in Healthcare Fieldwork services - please take a look!
For those interested in Healthcare Fieldwork services - please take a look!Paul Morgan
 
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...Greenlight Guru
 
What Is a CRO And How Can They Help You?
What Is a CRO And How Can They Help You?What Is a CRO And How Can They Help You?
What Is a CRO And How Can They Help You?Jan Balemans
 
About Pharmalink
About PharmalinkAbout Pharmalink
About Pharmalinktemreez
 
About Pharmalink
About PharmalinkAbout Pharmalink
About PharmalinkKotoole
 
About Pharmalink
About PharmalinkAbout Pharmalink
About Pharmalinkjcroskerry
 
About Pharmalink
About PharmalinkAbout Pharmalink
About Pharmalinklquinlan
 
1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDIT
1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDIT1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDIT
1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDITSCOTT SITTNER
 
Presentation on ISO 15189 documentation
Presentation on ISO 15189 documentationPresentation on ISO 15189 documentation
Presentation on ISO 15189 documentationGlobal Manager Group
 
Conformity assessment
Conformity assessmentConformity assessment
Conformity assessmenthjselamat
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of AuditMegha bhise
 
Rx 360 Audit Programs and BSI Sep15
Rx 360 Audit Programs and BSI Sep15Rx 360 Audit Programs and BSI Sep15
Rx 360 Audit Programs and BSI Sep15Vivian Berni
 

Similar to Mmc vendor qualification and management -dr. ursula schlictiger-may2012 (20)

MDSAP Certification: Success and Failures
MDSAP Certification: Success and FailuresMDSAP Certification: Success and Failures
MDSAP Certification: Success and Failures
 
What is pca pdf
What is pca pdfWhat is pca pdf
What is pca pdf
 
Exporting to Uganda ? What is PvOC ?
Exporting to Uganda ? What is PvOC ?Exporting to Uganda ? What is PvOC ?
Exporting to Uganda ? What is PvOC ?
 
For those interested in Healthcare Fieldwork services - please take a look!
For those interested in Healthcare Fieldwork services - please take a look!For those interested in Healthcare Fieldwork services - please take a look!
For those interested in Healthcare Fieldwork services - please take a look!
 
concept of validation
concept of validationconcept of validation
concept of validation
 
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...
 
Operon Strategist
Operon StrategistOperon Strategist
Operon Strategist
 
ISO 17065 .pdf
ISO 17065 .pdfISO 17065 .pdf
ISO 17065 .pdf
 
What Is a CRO And How Can They Help You?
What Is a CRO And How Can They Help You?What Is a CRO And How Can They Help You?
What Is a CRO And How Can They Help You?
 
Audits
AuditsAudits
Audits
 
About Pharmalink
About PharmalinkAbout Pharmalink
About Pharmalink
 
About Pharmalink
About PharmalinkAbout Pharmalink
About Pharmalink
 
About Pharmalink
About PharmalinkAbout Pharmalink
About Pharmalink
 
About Pharmalink
About PharmalinkAbout Pharmalink
About Pharmalink
 
1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDIT
1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDIT1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDIT
1.8.0 SITTNER CONOCO TRAIN HOW TO SURVIVE AN AUDIT
 
Presentation on ISO 15189 documentation
Presentation on ISO 15189 documentationPresentation on ISO 15189 documentation
Presentation on ISO 15189 documentation
 
Outsourcing BA and BE to CRO
Outsourcing BA and BE to CROOutsourcing BA and BE to CRO
Outsourcing BA and BE to CRO
 
Conformity assessment
Conformity assessmentConformity assessment
Conformity assessment
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
 
Rx 360 Audit Programs and BSI Sep15
Rx 360 Audit Programs and BSI Sep15Rx 360 Audit Programs and BSI Sep15
Rx 360 Audit Programs and BSI Sep15
 

More from Medpace

Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...Medpace
 
Getting Ahead of the Expanding Landscape: Radiopharmaceutical Dosimetry
Getting Ahead of the Expanding Landscape: Radiopharmaceutical DosimetryGetting Ahead of the Expanding Landscape: Radiopharmaceutical Dosimetry
Getting Ahead of the Expanding Landscape: Radiopharmaceutical DosimetryMedpace
 
Avoiding Common Pitfalls in Cell and Gene Therapy Trials
Avoiding Common Pitfalls in Cell and Gene Therapy TrialsAvoiding Common Pitfalls in Cell and Gene Therapy Trials
Avoiding Common Pitfalls in Cell and Gene Therapy TrialsMedpace
 
Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...Medpace
 
Considerations for the Next Wave of COVID-19 Development
Considerations for the Next Wave of COVID-19 DevelopmentConsiderations for the Next Wave of COVID-19 Development
Considerations for the Next Wave of COVID-19 DevelopmentMedpace
 
COVID-19 Product Development and Clinical Trials: Considerations from Europea...
COVID-19 Product Development and Clinical Trials: Considerations from Europea...COVID-19 Product Development and Clinical Trials: Considerations from Europea...
COVID-19 Product Development and Clinical Trials: Considerations from Europea...Medpace
 
Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...
Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...
Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...Medpace
 
Getting Ahead of the Evolving Landscape in Radiopharmaceuticals
Getting Ahead of the Evolving Landscape in RadiopharmaceuticalsGetting Ahead of the Evolving Landscape in Radiopharmaceuticals
Getting Ahead of the Evolving Landscape in RadiopharmaceuticalsMedpace
 
Challenges and Considerations in Clinical Development of "Targeted Therapies"...
Challenges and Considerations in Clinical Development of "Targeted Therapies"...Challenges and Considerations in Clinical Development of "Targeted Therapies"...
Challenges and Considerations in Clinical Development of "Targeted Therapies"...Medpace
 
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...Medpace
 
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...Medpace
 
Identifying High Performing Sites and Engaging Patients
Identifying High Performing Sites and Engaging PatientsIdentifying High Performing Sites and Engaging Patients
Identifying High Performing Sites and Engaging PatientsMedpace
 
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...Medpace
 
How Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare DiseaseHow Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare DiseaseMedpace
 
Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...
Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...
Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...Medpace
 
Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...
Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...
Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...Medpace
 
Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...
Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...
Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...Medpace
 
Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...
Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...
Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...Medpace
 
Gene Editing - Challenges and Future of CRISPR in Clinical Development
Gene Editing - Challenges and Future of CRISPR in Clinical DevelopmentGene Editing - Challenges and Future of CRISPR in Clinical Development
Gene Editing - Challenges and Future of CRISPR in Clinical DevelopmentMedpace
 
The CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory AffairsThe CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory AffairsMedpace
 

More from Medpace (20)

Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
 
Getting Ahead of the Expanding Landscape: Radiopharmaceutical Dosimetry
Getting Ahead of the Expanding Landscape: Radiopharmaceutical DosimetryGetting Ahead of the Expanding Landscape: Radiopharmaceutical Dosimetry
Getting Ahead of the Expanding Landscape: Radiopharmaceutical Dosimetry
 
Avoiding Common Pitfalls in Cell and Gene Therapy Trials
Avoiding Common Pitfalls in Cell and Gene Therapy TrialsAvoiding Common Pitfalls in Cell and Gene Therapy Trials
Avoiding Common Pitfalls in Cell and Gene Therapy Trials
 
Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...
 
Considerations for the Next Wave of COVID-19 Development
Considerations for the Next Wave of COVID-19 DevelopmentConsiderations for the Next Wave of COVID-19 Development
Considerations for the Next Wave of COVID-19 Development
 
COVID-19 Product Development and Clinical Trials: Considerations from Europea...
COVID-19 Product Development and Clinical Trials: Considerations from Europea...COVID-19 Product Development and Clinical Trials: Considerations from Europea...
COVID-19 Product Development and Clinical Trials: Considerations from Europea...
 
Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...
Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...
Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint ...
 
Getting Ahead of the Evolving Landscape in Radiopharmaceuticals
Getting Ahead of the Evolving Landscape in RadiopharmaceuticalsGetting Ahead of the Evolving Landscape in Radiopharmaceuticals
Getting Ahead of the Evolving Landscape in Radiopharmaceuticals
 
Challenges and Considerations in Clinical Development of "Targeted Therapies"...
Challenges and Considerations in Clinical Development of "Targeted Therapies"...Challenges and Considerations in Clinical Development of "Targeted Therapies"...
Challenges and Considerations in Clinical Development of "Targeted Therapies"...
 
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...
 
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
 
Identifying High Performing Sites and Engaging Patients
Identifying High Performing Sites and Engaging PatientsIdentifying High Performing Sites and Engaging Patients
Identifying High Performing Sites and Engaging Patients
 
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
 
How Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare DiseaseHow Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare Disease
 
Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...
Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...
Webinar: Oncology Trial Recruitment: Challenging Indications and Challenging ...
 
Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...
Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...
Webinar: Special Considerations for Managing Immuno-Oncology Studies: A New P...
 
Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...
Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...
Webinar: Getting Treatment Options to Rare Disease Patients Faster: Putting P...
 
Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...
Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...
Rare Disease Disorders and CNS Drug Development – Paving the Way for Precisio...
 
Gene Editing - Challenges and Future of CRISPR in Clinical Development
Gene Editing - Challenges and Future of CRISPR in Clinical DevelopmentGene Editing - Challenges and Future of CRISPR in Clinical Development
Gene Editing - Challenges and Future of CRISPR in Clinical Development
 
The CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory AffairsThe CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory Affairs
 

Recently uploaded

International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...ssuserf63bd7
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationAnamaria Contreras
 
Cyber Security Training in Office Environment
Cyber Security Training in Office EnvironmentCyber Security Training in Office Environment
Cyber Security Training in Office Environmentelijahj01012
 
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607dollysharma2066
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCRashishs7044
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCRashishs7044
 
Innovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdfInnovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdfrichard876048
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Seta Wicaksana
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxmbikashkanyari
 
Buy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy Verified Accounts
 
Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03DallasHaselhorst
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...ictsugar
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckHajeJanKamps
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMVoces Mineras
 
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent ChirchirMarketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchirictsugar
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCRashishs7044
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024Adnet Communications
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMintel Group
 

Recently uploaded (20)

International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement Presentation
 
Cyber Security Training in Office Environment
Cyber Security Training in Office EnvironmentCyber Security Training in Office Environment
Cyber Security Training in Office Environment
 
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
 
Innovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdfInnovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdf
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
 
Buy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail Accounts
 
Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQM
 
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent ChirchirMarketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchir
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR
 
Call Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North GoaCall Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North Goa
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 Edition
 
Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)
 

Mmc vendor qualification and management -dr. ursula schlictiger-may2012

  • 1. FOCUSED. TRUSTED. GLOBAL. Vendor Qualification Vendor Management from a CRO QM standpoint Dr. Ursula Schlichtiger Zurich May 9, 2012
  • 3. FOCUSED. TRUSTED. GLOBAL. Who is a Vendor? Anybody contracted or subcontracted to be involved in a clinical trial • Company • Person • Institution • Organisation
  • 4. FOCUSED. TRUSTED. GLOBAL. Vendors/ Subcontractors Sponsor bound per contract Vendors CRO bound per contract Vendors Subcontractors ? 1. Who holds the contract? 2. Which tasks are delegated?
  • 5. FOCUSED. TRUSTED. GLOBAL. Regulatory Background Europe (1)  Commission Directive 2005/28/EC “GCP Directive” http://ec.europa.eu/health/files/eudralex/vol-1/dir_2005_28/dir_2005_28_en.pdf  Chapter 2, THE SPONSOR, Article 7 A sponsor may delegate any or all of his trial-related functions to an individual, a company, an institution or an organization. However, in such cases, the sponsor shall remain responsible for ensuring that the conduct of the trials and the final data generated by those trials comply with Directive 2001/20/EC as well as this Directive.
  • 6. FOCUSED. TRUSTED. GLOBAL. Regulatory Background Europe (2)  European Commission: Eudralex Volume 10 Chapter IV Guidance Documents for Inspections: Annex IV to Guidance for the conduct of GCP Inspections - Sponsor and CRO“ (28 May 2008): http://ec.europa.eu/health/files/eudralex/vol10/chap4/annex_iv_to_guidance_for_the_conduct_of_gcp_inspections- o 2. SPONSOR OR CRO QUALITY SYSTEM INSPECTION o 3. SPECIFIC CLINICAL TRIAL INSPECTION
  • 7. FOCUSED. TRUSTED. GLOBAL. Regulatory Background Europe (cont 2) 2. SPONSOR OR CRO QUALITY SYSTEM INSPECTION: The aim of this kind of inspection is to evaluate the quality assurance and quality control systems established by the sponsor/CRO in order to assure that clinical trials are conducted and data are generated, recorded and reported in compliance with the protocol, GCP and applicable regulatory requirements. The following items should be reviewed in a sponsor/CRO system inspection: 2.3.8 Sponsor audit and quality assurance system The aim is to determine if the sponsor/CRO has established an audit system, as part of its own quality assurance system, in order to evaluate its activities related to clinical trials. It should be determined if the procedures include:  Audits of key clinical trial processes, including monitoring, data management, safety reporting, clinical study report production, archiving and computer system validation activities  Audits of contractors/subcontractors
  • 8. FOCUSED. TRUSTED. GLOBAL. Regulatory Background Europe (cont 2) The inspectors should also review:  The processes for communicating and addressing audit findings, including the format and distribution of audit reports  The procedures for dealing with serious and/or persistent GCP non- compliance  Audit trails  Procedures for generation and implementation of audit program(s)/plan(s) 2.3.9 Delegation of duties The aim is to verify the procedures for contracting/subcontracting of trial-related duties. Inspectors should examine the procedures related with:  Pre-selection and ongoing assessment of contractor/subcontractors  Documentation of duty delegation and its time recording  Handling contract amendments  Contracts should be reviewed (either specific ones or a sample)
  • 9. FOCUSED. TRUSTED. GLOBAL. Regulatory Background Europe (cont 2) 3. SPECIFIC CLINICAL TRIAL INSPECTION 3.1 Implementation and termination of the clinical trial The aim is to determine if all legal and administrative aspects of the clinical trial have been accomplished. Review:  Distribution of sponsor’s duties or functions  …… 3.8 Audit Determine:  If the clinical trial was audited and if audit reports exist  Qualifications of the auditors
  • 10. FOCUSED. TRUSTED. GLOBAL. Consequences  Sponsor and CRO: • Need a vendor qualification program » Internal vendors „Affiliates“ » External vendors „Subcontractors“ Risk based approach SOPs needed
  • 11. FOCUSED. TRUSTED. GLOBAL. Risk based Vendor Qualification 1. High risk: Delegation of critical tasks, e.g. - CROs - CMOs - Depots with QP release Audit mandatory o Medium risk: Delegation of routine tasks, e.g. - Courier - Depots without QP release - Translation companies paper based/ audit on case by case basis o Low risk: e.g. - provider of commercially available material paper based o Freelancers
  • 12. FOCUSED. TRUSTED. GLOBAL. CROs/ Subcontractors  Prequalification (paper based) • by means of questionnaire and supporting documents, e.g. » SOP Index » QM Manual » CVs  Qualification: Audit mandatory
  • 13. FOCUSED. TRUSTED. GLOBAL. Depots with and without QP release
  • 14. FOCUSED. TRUSTED. GLOBAL. Courier Services  Courier Service Companies • Qualification by means of questionnaire and supporting documents, e.g. » ISO certificates, index of quality manual, system description » Transport validation
  • 15. FOCUSED. TRUSTED. GLOBAL. Freelancers Risk based vs. Realistic approach paper based: CV Training records Personal experience audit of local situation: security
  • 16. FOCUSED. TRUSTED. GLOBAL. Goals?  All Key Service Providers should be qualified.  Keep a Qualified Vendor List  Only Service Providers from the Qualified Vendor List should be chosen  Train the operational functions
  • 17. FOCUSED. TRUSTED. GLOBAL. Process  Internal Vendor Qualification  Identification of vendors prior to contracts issued  Re-Qualification Audits foreseen every 2 years as per SOP includes "experience criteria"  Qualification after contracting only in exceptional cases
  • 18. FOCUSED. TRUSTED. GLOBAL. How can Operations help?  Let QA know which Key Service Providers you plan to work with  When selecting a vendor check the Qualified Vendor List  Use Vendor Audit Request Form for new vendors  Provide feedback on experience with vendors
  • 19. FOCUSED. TRUSTED. GLOBAL. Request a Vendor Audit!
  • 20. FOCUSED. TRUSTED. GLOBAL. Inspection/ Audit Questions 1. Are SOPs available? 2. Do you use vendors? 3. What kind of vendors? 4. Which are internal and which are external vendors? 5. How do you qualify them? 6. How often do you re-qualify them? 7. Which vendors have been qualified? 8. Why do you also allow paper-based qualification? 9. Can we get insight in the audit reports? 10. Does QA have GCP/ GLP and GMP experience? 11. Do you audit against Task Allocation?
  • 21. FOCUSED. TRUSTED. GLOBAL. Thank you! Any Questions? o Medpace Medical Consulting GmbH Nussbaumstr. 10 80336 Munich Germany Tel: +49 (0) 89 673 79 16 Fax: +49 (0) 89 670 21 00 E-mail: info-MC@medpace.com